Primecap Management Co. CA Sells 1,330 Shares of Sanofi (NASDAQ:SNY)

Primecap Management Co. CA decreased its position in shares of Sanofi (NASDAQ:SNY) by 0.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,115,998 shares of the company’s stock after selling 1,330 shares during the quarter. Primecap Management Co. CA’s holdings in Sanofi were worth $64,315,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of SNY. POM Investment Strategies LLC bought a new stake in Sanofi during the 2nd quarter valued at $25,000. Northwest Investment Counselors LLC purchased a new stake in Sanofi in the third quarter worth $29,000. Concord Wealth Partners lifted its holdings in Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the last quarter. Arrow Financial Corp purchased a new stake in shares of Sanofi during the 2nd quarter valued at approximately $35,000. Finally, Fortitude Family Office LLC boosted its holdings in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the period. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Performance

NASDAQ:SNY opened at $47.99 on Friday. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The firm’s fifty day simple moving average is $53.88 and its 200 day simple moving average is $52.16. The stock has a market cap of $121.79 billion, a P/E ratio of 24.48, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.55 earnings per share. As a group, research analysts predict that Sanofi will post 4.29 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on SNY. Argus boosted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Sanofi currently has an average rating of “Moderate Buy” and an average price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.